BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ablynx Initiates Phase I Study With ALX-0171 for the Treatment of Respiratory Syncytial Virus (RSV)


12/13/2011 8:54:33 AM

GHENT, BELGIUM--(Marketwire - December 13, 2011) - Ablynx [Euronext Brussels: ABLX] today announced that it has initiated a Phase I study in healthy volunteers with ALX- 0171, the first Nanobody in clinical development to be delivered by inhalation. ALX-0171 is being developed for the treatment of respiratory syncytial viral (RSV) infections.

The Phase I study is a single-centre, randomised, placebo-controlled trial that will investigate the safety, tolerability and PK profile of ALX-0171 in healthy volunteers. The study will include a single ascending dose part with six dose levels, which is expected to recruit 44 subjects, followed by a multiple dose part that is expected to recruit 16 subjects. Results of the study are anticipated during the second half of 2012.

Dr Edwin Moses, CEO and Chairman at Ablynx, commented: "We believe there is a high unmet need for a therapeutic treatment of RSV infection. ALX-0171 is the first Nanobody to enter clinical development that is administered through inhalation rather than injection. It has the potential to become a first-in- class therapeutic for RSV infections. This alternative route of administration in an acute disease setting is a good example of the competitive differentiation and advantages our Nanobody technology platform can bring. We are looking forward to seeing the results of this first-in-man trial, which are expected during the third quarter of 2012."


About RSV

RSV is a respiratory virus that infects the lungs and respiratory tract. Most healthy people recover from an RSV infection within one or two weeks. However, the infection can be much more severe in immune-compromised individuals, the elderly, infants with cardio-pulmonary disease and premature babies. RSV is the most common cause of bronchiolitis (inflammation of the bronchioles, the smallest air passages of the lungs) and pneumonia in children younger than one year old, and is increasingly being recognised as an important cause of respiratory illness in the elderly. Today, there are no widely accepted established antiviral agents available for the treatment of RSV. High-risk infants can be protected with a prophylactic drug that is used to protect against RSV infections. ALX-0171 has the potential to become a first-in- class therapeutic for the treatment of RSV and may address an even larger patient population beyond high-risk infants in the therapeutic setting.

Complete version of the press release:

http://hugin.info/137912/R/1570756/488477.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

[HUG#1570756]


For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact


Read at BioSpace.com


Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->